OBJECTIVE: Accurate cancer risk prediction is hindered by complex, multi-layered immune interactions, and traditional tissue biopsies are invasive and lack scalability for large-scale or repeated assessments. Peripheral blood offers a minimally invasive and accessible alternative for immune profiling. This study aims to develop CAMFormer, a deep learning framework that integrates multimodal peripheral blood-derived immune features for precise, non-invasive early cancer risk prediction. METHODS: CAMFormer combines mRNA expression, immune cell frequencies, and TCR diversity index, leveraging a cross-attention-based multimodal Transformer to capture cross-scale immune interactions. RESULTS: In five-fold cross-validation, CAMFormer achieved an AUC of 0.92 and an F1-score of 0.85 on the validation set, outperforming unimodal and baseline methods. CONCLUSION: These results highlight the potential benefits of integrating multimodal immune features with cross-attention mechanisms for early cancer detection and for guiding future personalized immunotherapy studies.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: